A year in review: AI’s evolving role in drug discovery and development in 2023

[Image courtesy of ipopba via iStock Photo]

In the realm drug discovery, AI is making waves, and 2023 could potentially be a pivotal year for this technology. As the technology enters the popular consciousness, pharma employees are wondering “why they can’t have similar AI-driven tools for their professional tasks,” said Diane Wuest, head of digital R&D at Sanofi, in a recent interview. 

Still, some executives at pharma companies worry about AI’s potential to generate misleading data, as the Economist notes. Such fears are not entirely unfounded. While most headlines continue to tout AI’s promise in the field, there was a notable failure in 2023: an AI-aided drug failed a pair of phase 3 trials.

This article provides an overview of AI’s increasing traction in drug discovery and development in 2023 from January to early August. We’ll update it as the year progresses. 

Read more
  • 0